Xywav
| Combination of | |
|---|---|
| Calcium oxybate | Central nervous system depressant |
| Magnesium oxybate | Central nervous system depressant |
| Potassium oxybate | Central nervous system depressant |
| Sodium oxybate | Central nervous system depressant |
| Clinical data | |
| Trade names | Xywav |
| Other names | JZP-258 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a621001 |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Xywav (calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate) is a fixed-dose combination medication used to treat cataplexy or excessive daytime sleepiness. It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate. It is a central nervous system (CNS) depressant and it is taken by mouth.
It is manufactured by Jazz Pharmaceuticals and was approved for medical use in the United States in July 2020.
Category:
- Drugs not assigned an ATC code